Sanofi

The corporation was formed in December 2004 by merging two groups of companies: Sanofi-Sintelabo and Aventis. The merger actually occurred as a result of the purchase by Sanofi-Sintelabo of SA (France) of a controlling stake in the parent company of Aventis Group.

• The shares of the Sanofi Group are listed on the Paris (EURONEXT: SAN) and New York (NYSE: SNY) stock exchanges.
• 4 research clusters in Asia, France, Germany and North America

Business in Russia

Sanofi occupies one of the leading positions in the Russian pharmaceutical market, offering its patients a wide range of original medicines and generics in key therapeutic areas such as diabetes mellitus, oncology, cardiovascular diseases, internal diseases, diseases of the central nervous system, vaccinoprophylaxis and rare diseases.

{{main 'Sanofi-Aventis
}}

Performance indicators

2021: 8th in the world in terms of prescription drug sales: $38.9 billion

Data for 2021

History

2024: Heartburn drug Zantac causes cancer. Sanofi to pay $100M to settle 4,000 claims

Sanofi will pay more than $100 million to settle about 4,000 lawsuits accusing the French drugmaker of failing to warn users that its heartburn drug Zantac could cause cancer.

2023: $2.9 billion Provention Bio purchase

On March 13, 2023, the French corporation Sanofi announced an agreement to acquire the American biopharmaceutical company Provention Bio. The transaction amount is $2.9 billion. Read more here.

2022

In the drug against multiple sclerosis, the rights to which Sanofi bought for $3.7 billion, found serious side effects

In July 2022, the American medical regulator FDA ordered the pharmaceutical company Sanofi to stop testing the drug against multiple sclerosis. The cause was dangerous side effects. Seeing cases of drug-induced liver damage, authorities imposed a partial clinical ban on phase three trials of the drug, further reinforcing doubts about the appropriateness of Sanofi's takeover of Principia Biopharma. Read more here.

Will pay 450 thousand euros to a family where a child with autism was born because of the drug

In mid-May 2022, the French pharmaceutical laboratory Sanofi was ordered to pay €450,000 in compensation to a family whose child was born with developmental disabilities caused by his mother taking Depakine for epilepsy. Read more here.

Recall of Phosphalugel in Russia due to exceeding the permissible lead limit

In March 2022, the Federal Service for Supervision in the Field health care () Roszdravnadzor based on the information of LLC "" Opella Helskea announced the decision of Opella Helskea France SAS (included in the group), Sanofi which is the holder of the marketing authorization P N012655/01 from the 05.03.2009 for drugs with the trade name "Phosphalugel," withdraw from circulation some batches of the drug due to the detection in them of exceeding the permissible daily limit of lead content. We are talking about the drug "Phosphalugel, oral gel 16 g, sachet (20), cardboard packs." More. here

2021

Purchase of the developer of drugs for antitumor therapy Amunix Pharmaceuticals for $1 billion

On December 21, 2021, Sanofi announced the purchase of Amunix Pharmaceuticals, an immuno-oncology drug company, for $1.2 billion. Read more here.

Purchase of the Austrian vaccine developer from acne Origimm Biotechnology

At the end of November 2021, the French medical company Sanofi acquired Origimm Biotechnology. The financial component of the transaction was not disclosed. Read more here.

Purchase of the biopharmaceutical company Kadmon for $1.9 billion

On September 8, 2021, French drugmaker Sanofi said it would buy American biopharmaceutical company Kadmon for $1.9 billion. Read more here.

$3.2 billion purchase of mRNA specialist Translate Bio

In August 2021, it became known that Sanofi SA will pay $3.2 billion for the acquisition of Translate Bio, a mRNA company. It will also give Sanofi a platform to further develop drugs and vaccines using this technology.

This technology has proven itself well during the COVID-19 pandemic, its effectiveness in other diseases has not yet been proven, but several large companies, including Pfizer and GlaxoSmithKline, are working on mRNA vaccines against influenza and other infectious diseases, hoping that they can be more effective and easy to produce than traditional analogues.

Penalty for concealing side effects of Plavix

In mid-February 2021, the court forced Bristol-Myers Squibb and Sanofi to pay the state of Hawaii more than $834 million for concealing the side effects of the anti-platelet drug Plavix, which is used to prevent repeated myocardial infarction or stroke. Read more here.

Purchase of immuno-oncology developer Kymab

On January 11, 2021, Sanofi announced the acquisition of Kymab. The transaction value is $1.1 billion. At the same time, the terms of the agreement provide for additional payments in the amount of up to $350 million if certain indicators are achieved by the British developer of immuno-oncological drugs. What kind of tasks are in question is not specified. Read more here.

2020

Purchase of the American Principia Biopharma for $3.7 billion

In August 2020, the French pharmaceutical company Sanofi agreed to purchase the American Principia Biopharma for about $3.7 billion.

According to the joint statement, Sanofi will buy the outstanding shares of Principia for $100 dollars per paper with money. The total value of the company will be about $3.68 billion on a fully diluted basis, and the premium to the share price of Principia Biopharma at $90.74 at the close of trading on August 14 is 10%.

Sanofi said the acquisition of Principia Biopharma, which develops treatments for severe immune diseases, will strengthen the company's research potential in areas such as autoimmune and allergic diseases.

Sacking 1,700 people in pursuit of €2bn savings

At the end of June 2020, Sanofi reported about 1,700 job cuts. The company is ready to discuss possible measures with union representatives. The head of the drug production department, Paul Hudson, claims that this step will help the company reduce costs and save up to 2 billion euros.

Management will meet with staff representatives on July 3 and 6 to outline a restructuring plan. Sources asked for the information to be released anonymously as the plans are still considered confidential. The reorganization is expected to capture several European countries and some countries outside the region, as well as all Sanofi units except Genzyme, the rare disease vaccine and drug development unit.

Sanofi reported about 1,700 job cuts. The company is ready to discuss possible measures with union representatives

Three Reuters sources said the cuts could capture about 1,000 jobs in France. However, one of the sources claims that the cuts will be carried out gradually over a three-year period.

Discussions of these measures began back in December 2019, after Paul Hudson announced plans to cut the company's costs by 2 billion euros ($2.24 billion) by 2022.

Due to the COVID-19 pandemic, restructuring plans had to be postponed, but all these measures are included in the director general's action plan, "says one of the interlocutors.

Hudson pledged additional resources to those units he believes will help Sanofi take a lead in certain areas. The company is investing €610 million in two French businesses, aiming to turn them into a hub dedicated to vaccine research, development and production. About 200 new jobs are expected^[1] be created in one of these^[2]

2019

Sale of Seprafilm Surgical Materials Business

In early December 2019, Baxter bought Seprafilm's surgical materials business from Sanofi for $350 million. The deal is due to close by the end of the first quarter of 2020. Read more here.

Abbott, Medtronic, Sanofi and Novo Nordisk started sharing diabetic data

In mid-September 2019, Abbott and Medtronic announced data sharing agreements for digital diabetes care solutions. For example, Abbott is partnering with Sanofi to integrate glucose assessment and insulin delivery tools. And Medtronic is partnering with Novo Nordisk to use insulin dosing data from smart pen syringes in its glucose monitoring devices. Read more here.

2017

• 15.3% of sales revenue is invested in development, By 2020, investment in research will increase from 5 to 6 billion euros

2016: Sanofi and Beringer Ingelheim combine divisions

On June 27, 2016, Sanofi and Beringer Ingelheim (BI) announced the signing of several agreements securing agreements on the strategic exchange of assets: the veterinary division of Sanofi (Merial) for the over-the-counter division of Beringer Ingelheim. The transaction is expected to be completed at the end of 2016, but until that moment it must be approved by regulatory authorities in different countries. The integration of the over-the-counter division of Beringer Ingelheim into the structure of Sanofi and Merial in BI will begin after the completion of the transaction.

The over-the-counter division of Beringer Ingelheim, whose value is estimated at 6.7 billion euros, will be integrated into the structure of Sanofi, and the latter's company Merial, which is estimated at 11.4 billion euros, will be integrated into the structure of Beringer Ingelheim. As compensation for the difference in the value of assets, the BI will pay Sanofi 4.7 billion euros. Taking into account the income from the acquired over-the-counter unit, its integration into the company's business, as well as the allocation of part of the funds from Sanofi's net revenue for the repurchase of shares in its veterinary drugs division, the company expects zero profit per share in 2017, followed by an increase in its value.

The unified line of veterinary drugs "Merial" and "Beringer Ingelheim," the general technological base for the production of antiparasitic drugs, vaccines and specialized drugs will make it possible to occupy a more favorable position in key growing market segments. Taking into account the results of global sales in 2015, it is expected that the veterinary division of Beringer Ingelheim will more than double its sales to 3.8 billion euros.

After the completion of the deal, Sanofi integrates the over-the-counter division of the BI into its business in all countries except China. Taking into account the results of global sales in 2015, it is expected that the sales volume of the combined over-the-counter company will amount to 4.9 billion euros. By expanding its own line with new high-quality products and brands, Sanofi will strengthen its position in a number of key areas of activity: analgesics, antihistamines, antiprostudal drugs, drugs for women's health, treatment of diseases of the gastrointestinal tract, as well as vitamins, minerals and dietary supplements.

In accordance with the agreements reached between the companies at the very beginning of the negotiations, it was decided that Lyon and Toulouse (France) would become the main operating centers of the veterinary division of Beringer Ingelheim. Among other things, the following activities will be carried out there: commercial, research and production - in Lyon, and the company's production center will operate in Toulouse. Since the American market is extremely important for Merial, Beringer Ingelheim will pay special attention to the company's activities in the United States . Germany will become the main business platform of Sanofi's over-the-counter division, in particular, for work in the areas of drugs for the treatment of the gastrointestinal tract and antiprostudal drugs.

More about the over-the-counter division "Beringer Ingelheim"

The over-the-counter division of Beringer Ingelheim ranks eighth in the world in the list of the largest manufacturers of over-the-counter drugs. In 2015, sales of the division amounted to 1.51 billion euros - 10% of the total net sales of BI. The company aims to create and develop sustainable solutions that allow you to effectively develop high-quality products for your customers. The most famous brands of the OTC division of Beringer Ingelheim are: antispasmodic Buscopan® (in 2015 sales amounted to 223 million euros; the main sales markets for the drug - Europe and developing countries), the laxative "Dulcolax®" (in 2015 sales amounted to 225 million euros; sold in more than 40 countries, especially popular in the United States), Pharmaton® multivitamins (in 2015 sales amounted to 140 million euros, most of which were sold in developing countries), cough treatment drug "Mucosolvan®" (in 2015 sales amounted to 168 million euros, mainly sold in Russia (under the name "Lasolvan") and Germany) and "Bisolvon®" (in 2015 sales amounted to 96 million euros, the drug is represented in a number of countries, including Spain and Italy) and "Mucoangin®/Lysopaine®" (sales amounted to EUR 54 million in 2015).

Read more about Sanofi's over-the-counter division

In 2015, global sales of Sanofi's over-the-counter drug division totaled €3.4 billion. Its most famous brands are: Allegra® antihistamines (in 2015 sales amounted to 424 million euros) and Nasacort® (in 2015 sales amounted to 122 million euros), Doliprane® painkillers (in 2015 sales amounted to 303 million euros), "No-Spa®" (in 2015 sales amounted to 88 million euros) and Dorflex® (in 2015 sales amounted to 81 million euros), drugs for the gastrointestinal tract "Essentiale®" (in 2015 sales amounted to 196 million euros), Enterogermina® (in 2015 sales amounted to 161 million euros) and Maalox® (sales amounted to 97 million euros in 2015), Lactacyd® women's health products (in 2015 sales amounted to 114 million euros) and the complex of vitamins and minerals "Magné B6®" (in 2015 sales amounted to 103 million euros). In 2015, 48.1% of the company's sales were in developing countries, 26.2% in the United States, and 18.6% in Western Europe.

More about "Merial"

Merial is one of the leading innovative companies in the veterinary market. The company offers a wide range of drugs to treat and promote animal health. Merial has three main activities: pet products, farm animal products, and veterinary products. The company's drugs and vaccines are aimed at preventing and treating diseases, they cover more than 200 diseases and disorders that affect animals of a wide variety of species. The company employs 6,900 people. Merial operates in more than 150 countries. Global sales in 2015 amounted to 2.5 billion euros. "Merial" is owned by Sanofi's company. More information can be found on the company's website www.merial.com

The best known "Merial" products for pet health are: "Frontline®," "Heartgard®," "NexGard®," "Broadline®" and "Purevax®"; for farm animals: "Vaxxitek®," "Eprinex®," "Ivomec®," "Longrange®," "Circovac®" and "GastroGard®." Innovation and high quality products, which provide 13 research and 15 production centers around the world, have always been key priorities in Merial's activities.

More information about the veterinary division "Beringer Ingelheim"

The veterinary division of Beringer Ingelheim ranks 6th in the world. The company offers innovative solutions to treat and promote the health of many animal species. The company employs 3,800 employees worldwide. In 2015, sales amounted to almost 1.36 billion euros - 9% of the BI's sales. The main products of the veterinary division of Beringer Ingelheim are: Ingelvac Circoflex® (in 2015 sales amounted to 281 million euros), Metacam® (in 2015 sales amounted to 101 million euros), Ingelvac PRRS® (in 2015 sales amounted to 99 million euros) and Duramune® (in 2015 sales amounted to 88 million euros).

The veterinary division of Beringer Ingelheim is one of the world leaders in the production of vaccines for pigs and cattle, as well as in the development of special veterinary drugs. The veterinary division investigates and develops animal drugs in the United States, Germany, China, Mexico and Japan. Being focused on innovation, the veterinary division of Beringer Ingelheim constantly invests 12% of sales profits in research.